Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI® PharmiWeb.com (press release) ... three principal products AVONEX® (interferon beta-1a) TYSABRI and RITUXAN® (rituximab) the importance of TYSABRI's sales growth uncertainty of success in commercializing and developing other products product competition the occurrence of adverse ... |
